2.70Open2.82Pre Close85 Volume1.83K Open Interest15.00Strike Price27.37KTurnover484.28%IV37.04%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry3.85Extrinsic Value100Contract SizeAmericanOptions Type-0.2723Delta0.0238Gamma4.72Leverage Ratio-0.2462Theta-0.0021Rho-1.29Eff Leverage0.0096Vega
Jasper Therapeutics Stock Discussion
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response
10 of 12 participants in the 120mg cohort achieved a complete response
No serious adverse events; no grade 3 or higher adverse events reported
Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort
Company to host conference call and webinar today at 8:00 ...
Microsoft $Microsoft (MSFT.US)$ (office currently has nearly 400 million users, OficARPU increases after the acquisition of OpenA and Azurez-related...
No comment yet